1. Mid-Atlantic Permanente Medical Group, Rockville, MD, USA; 2. Lahey Hospital and Medical Center, Burlington, MA, USA; 3. University of Missouri-Kansas City, Kansas City, MO, USA
Over the past decade, the emergence of transcatheter aortic valve replacement (TAVR) has opened a new world of options for treatment of patients with severe symptomatic aortic stenosis (AS). Trials in intermediate- and high-risk surgical patients have demonstrated TAVR to be non-inferior to surgical aortic valve replacement (SAVR)1,2,3. Nonetheless, given the much higher acquisition cost of a TAVR device compared with a surgical bioprosthesis, the cost-effectiveness of this approach has been questioned. While transfemoral TAVR was found to be reasonably cost-effective compared with SAVR in the high-risk population4,5, the economics of TAVR appear to be even more favourable in ...
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com